GB2578008A - 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment - Google Patents

1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment Download PDF

Info

Publication number
GB2578008A
GB2578008A GB1916084.5A GB201916084A GB2578008A GB 2578008 A GB2578008 A GB 2578008A GB 201916084 A GB201916084 A GB 201916084A GB 2578008 A GB2578008 A GB 2578008A
Authority
GB
United Kingdom
Prior art keywords
pyrrolin
acetyl
nitro
phenyl
mmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1916084.5A
Other versions
GB201916084D0 (en
GB2578008B (en
Inventor
Kuznecovs Jevgenijs
Veinbergs Grigorijs
Vorona Maksims
Domraceva Ilona
Kanepe-Lapsa Iveta
Leonciks Ainars
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of GB201916084D0 publication Critical patent/GB201916084D0/en
Publication of GB2578008A publication Critical patent/GB2578008A/en
Application granted granted Critical
Publication of GB2578008B publication Critical patent/GB2578008B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to medicine, in particular to medical use of 1-acetyl-5-nitro-4- phenyl-3-pyrrolin-2-one exhibiting metalloproteinase and angiogenesis inhibiting properties for the treatment of cancer.

Claims (2)

Claims
1. Metalloproteinase (MMP) inhibitor l-acetyl-5-nitro-4-phenyl-3-pyrrolin-2- one (1) for use in the treatment of cancer accompanied by MMP over expression leading to the degradation of the extracellular matrix and to the development of metastasis.
2. MMP inhibitor according to Claim 1, wherein l-acetyl-5-nitro-4-phenyl-3- pyrrolin-2-one inhibits MMP-2 and MMP- 14.
GB1916084.5A 2017-07-24 2018-03-22 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment Active GB2578008B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-17-51A LV15384B (en) 2017-07-24 2017-07-24 1-acetyl-5-nitro-4-phenyl-3-pyrrolin-2-one for use in the treatment of cancer
PCT/IB2018/051917 WO2019021067A1 (en) 2017-07-24 2018-03-22 1-acetyl-5-nitro-4-phenyl-3-pyrrolin-2-one for use in cancer treatment

Publications (3)

Publication Number Publication Date
GB201916084D0 GB201916084D0 (en) 2019-12-18
GB2578008A true GB2578008A (en) 2020-04-15
GB2578008B GB2578008B (en) 2022-03-16

Family

ID=59858757

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1916084.5A Active GB2578008B (en) 2017-07-24 2018-03-22 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment

Country Status (3)

Country Link
GB (1) GB2578008B (en)
LV (1) LV15384B (en)
WO (1) WO2019021067A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037171A2 (en) * 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
AU746853B2 (en) 1997-06-21 2002-05-02 Roche Diagnostics Gmbh Barbituric acid derivatives with antimetastatic and antitumor activity
CA2572047C (en) 2004-07-21 2014-04-08 Applied Research Systems Ars Holding N.V. Octahydropyrrolo[2,3,c]pyridine derivatives and pharmaceutical use thereof
KR100829257B1 (en) 2006-06-22 2008-05-14 부경대학교 산학협력단 Caboxylated glucosamine compounds for inhibiting the the activation and expression of matrix metalloproteinase-9 in human fibrosacroma cells and matrix metalloproteinase-9 inhibitors contanining the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037171A2 (en) * 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG X C ET AL, "Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 10, doi:10.1016/J.EJMECH.2007.12.020, ISSN 0223-5234, (20081001), Abstract, introduction; table 1 *

Also Published As

Publication number Publication date
GB201916084D0 (en) 2019-12-18
LV15384A (en) 2019-02-20
WO2019021067A1 (en) 2019-01-31
LV15384B (en) 2019-05-20
GB2578008B (en) 2022-03-16

Similar Documents

Publication Publication Date Title
CL2021001292A1 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2022000711A (en) Parp1 inhibitors.
MX2021009246A (en) Immunomodulators, compositions and methods thereof.
MX2021001186A (en) Purinones as ubiquitin-specific protease 1 inhibitors.
WO2018134685A3 (en) Compounds
MX2021011826A (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof.
MX2023002507A (en) Cd73 inhibitors.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2022007155A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof.
MX2022008478A (en) Low-dose brimonidine combinations and uses thereof.
BR112022008365A2 (en) CD73 INHIBITORS
PH12018502242A1 (en) Imidazolone compounds as human neutrophil elastase inhibitors
MX2021015770A (en) Macrocyclic inhibitors of mcl-1.
MX2020012800A (en) Cannabinoids and uses thereof.
PH12021550122A1 (en) Solubilized apyrases, methods and use
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
WO2019040105A3 (en) Compounds, salts thereof and their use in the treatment of diseases
MX2019010218A (en) Pyrazole derivatives as bromodomain inhibitors.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
ZA201908446B (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
GB2578008A (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
MX2022007874A (en) Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof.
MX2020013805A (en) Pyridopyrimidinone derivatives for use as axl inhibitors.